KLRS
Kalaris Therapeutics, Inc.
Latest Form 4:Purchase$1.2MbyAKKARAJU SRINIVAS (Director, 10% Owner) · filed May 22, 2026
Kalaris Therapeutics, Inc. (KLRS) has 4 SEC Form 4 filings (7 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: May 22, 2026.
Insiders have net bought $6.2M over the trailing 6 months. The largest single insider purchase in this window was $5.0M by Director, 10% Owner AKKARAJU SRINIVAS on Dec 18, 2025.
- Industry:Biotechnology
- CEO:Andrew Oxtoby
- Employees:20
- HQ:Berkeley Heights, NJ, US
- IPO:2020-07-30
Insider Buying
$6.2M
reported purchases (SEC code P)
Insider Selling
$13K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$97.1M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
AKKARAJU SRINIVASFirst in 3 months | Director, 10% Owner | Purchase | 244,300 | $1.2M | May 22 | SEC ↗ |
Hagen Brett RFirst filing | Chief Accounting Officer | Sale | 1,915 | $13K | Mar 23 | SEC ↗ |
| Director, 10% Owner | Purchase | 479,847 | $5.0M | Feb 17 | SEC ↗ |
Related companies
Kalaris Therapeutics, Inc. is in the Healthcare sector.